Although lupus is, by definition, associated with genetic and immunological factors, its molecular mechanisms remain unclear. The up-to-date research findings point out that various genetic and epigenetic factors, especially gene-specific and site-specific methylation, are believed to contribute to the initiation and development of systemic lupus erythematosus (SLE). This review presents and summarizes the association between abnormal DNA methylation of immune-related cells and lupus-like diseases, as well as the possible mechanisms of immune disorder caused by DNA methylation, aiming at a better understanding of the roles of aberrant DNA methylation in the initiation and development of certain forms of lupus and providing a new insight into promising therapeutic regimens in lupus-like diseases.
Introduction
Systemic lupus erythematosus (SLE), characterized by T cell hyperactivity and B cell over-stimulation, is a prototypical systemic autoimmune disease, resulting in multiple organ damage and diverse clinical manifestations [1] . Currently, SLE is caused mainly by genetic susceptibility identified by genomewide association studies (GWAS) and environmental factors, including ultraviolent light, smoking and alcohol, but it has unpredictable and unknown molecular mechanisms [2] [3] [4] .
Accounting for approximately 10% of all SLE in the United States, drug-induced lupus is an immune-mediated but non-immunoglobulin (Ig)E immune-related drug reaction [5] . Previous researches have put forward several hypotheses for the mechanism of drug-induced autoimmunity, suggesting that there was no single simple mechanism by which drugs induced lupus [6] .
Recent technological advances have led to great breakthroughs in the identification of susceptibility factors involved in SLE [7] , among which DNA methylation alterations give rise to great expectations for clinicians and researchers. Incomplete concordance for SLE has been found in homozygotic twins, suggesting that environmental and epigenetic factors may exert an influence on the onset of disease [8] . Increasing evidence has revealed that SLE can be accelerated by environmental triggers and certain types of drugs, which were known to cause DNA methylation alterations [9, 10] . This review summarizes up-to-date data demonstrating the role that DNA methylation plays in the pathogenesis of SLE, providing novel and practical references for the diagnosis and therapies for lupus-like diseases.
DNA methylation alterations in lupus

DNA methylation
DNA methylation, taking place at the cytosine residues in cytosine-phosphate-guanosine (CpG) dinucleotides, involves the formation of 5-methylcytosines at the 5' position of the cytosine pyrimidine ring [11] . Generally mediated by DNA methyltransferases (DNMTs), DNA methylation is associated with gene repression, leading to transcriptional silencing. Currently, although the mechanisms by which DNA methylation represses gene expression are incompletely understood, it is generally believed that DNA methylation may exert its role by binding directly with specific transcription factors or indirectly with methyl-CpG-binding proteins (MBDs) [12] [13] [14] [15] [16] .
Moreover, approximately 60% of normally unmethylated gene promoters are associated with CpG islands and hypomethylation of the gene promoter contributes to the activation of gene transcription, whereas hypermethylation of the gene promoter is associated with gene inactivation [17] .
With the development of high-throughput approaches, useful methods are used more frequently to assess DNA methylation profiles. Currently, there are three main approaches to detect 5-methylcytosine (5MC) and 5-hydroxymethylcytosine (5HMC) [18] . First, the rapid pace of advances in next-generation sequencing improved 5MC/ 5HMC, rendering them increasingly inexpensive and accessible. Secondly, methyl-sensitive restriction enzymes cut DNA based on methylation status of cytosines within their recognition sequences. Thirdly, the bisulphite-based method allowed high-throughput quantitative methylation analysis at certain loci in hundreds of samples, or as a follow-up to genomewide profiling.
As a highly heritable epigenetic feature, DNA methylation plays a vital role in many cellular processes, such as chromatin structure, transcription and embryonic development [19] . In turn, by affecting DNA methylation alterations, certain susceptibility factors may also be involved in the pathogenesis of many common autoimmune diseases, such as lupus (Table 1) .
Abnormal DNA methylation in lupus T cells
Abnormal DNA methylation in lupus CD4
1 T cells. The first research by Richardson's group found that global DNA hypomethylation on CD4 1 T cells was associated with T cell autoreactivity in active lupus patients [66] , revealing the relationship between abnormal DNA methylation status and SLE. Further study discovered that 5-azacytidine, an inhibitor of DNA methylation, was correlated with the disease activity of lupus patients [20] . It was generally considered that DNA methylation reflects specific gene expression, determining the chromatin structure of T cells. However, an increasing number of studies focus upon specific cell types, as well as certain SLE-relevant genes. Regulatory factor X-box 1 (RFX1), a transcription factor belonging to the regulation factor for the X-box protein family, regulates DNA methylation in CD4 1 T cells by decreasing H3K9 trimethylation in CD11a and CD70 promoter regions, triggering over-expression of CD11a and CD70 [21, 22] . In addition, the demethylation of DNA damage-inducible 45 alpha (Gadd45a) is correlated positively with CD11a/CD70 expression in lupus patients [23] , with high mobility group box protein 1 (HMGB1) having been found to be involved in DNA demethylation through the binding to Gadd45A [24] . In addition to CD11a and CD70, over-expression of lymphocyte function-associated antigen 1 (LFA-1), perforin and CD40LG is also the consequence of relevant DNA hypomethylation in CD4 1 T cells, which might result in autoantibody formation and contribute to the pathogenesis of SLE [25, 27] . Luo et al. also found that demethylation of the perforin contributes to perforin overexpression in subacute cutaneous lupus erythematosus (SCLE) CD4 1 T cells [26] . In addition, Zhou et al. demonstrated that demethylation of female lupus CD4
1 T cells over-stimulates B cells to produce IgG, due to reactivation of the inactive X chromosome in females [28] . Furthermore, killer-cell immunoglobulin-like receptors (KIRs), a family of cell surface proteins expressed on natural killer (NK) cells, and a small portion of T cells, are suppressed primarily by DNA methylation in CD4
1 T cells, enhancing production of IFN-g and macrophage in lupus patients [29, 30] . Wu et al. found that 17b-oestradiol down-regulated DNMT1 activity and enhanced global DNA hypomethylation in female SLE CD4 1 T cells [31] . In recent years, several studies have indicated that demethylation of inflammatory cytokine genes, such as interleukin (IL)210, IL-13, IL-4 and IL-6, in CD4
1 T cells might participate in the progression of SLE [32, 33] . Girdhari et al. identified that the hypermethylation of forkhead box protein 3 (FoxP3), a winged-helix family transcription factor, is important for delineating T cell development and differentiation in naive CD4 1 T cells [32] . E4BP4, a major transcription factor, regulates CD40L expression directly by altering methylation of the CD40L loci in SLE CD4 1 T cells [34] . Recently, Wu et al. found that the methylation levels of the long terminal repeats (LTRS) of human endogenous retroviruses (HERVs) encoded within the genomes of all higher eukaryotes is inhibited in lupus CD4 1 T cells, and is associated closely with lupus progression [35] .
Recently, high-throughput approaches have enabled us to gain a glimpse of genome-wide DNA methylation profiles in CD4 1 T cells. Javierre et al. confirmed that the aberrant methylation of eight genes, interferon (IFN) gamma receptor 2 (IFNGR2), matrix metallopeptidase 14 (MMP14), lipocalin 2 (LCN2), colony-stimulating factor 3 receptor (CSF3R), platelet and endothelial cell adhesion molecule 1 (PECAM1), CD9, absent in melanoma 2 (AIM2) and pancreatic and duodenal homeobox 1 (PDX1), are functionally relevant to SLE [67] . Genome-scale DNA methylation analysis identified the hypomethylation of IFN-regulated genes, including IFNinduced protein 44-like (IFI44L), IFN-induced protein with tetratricopeptide (IFIT1), IFIT3, MX dynamin-like GTPase 1 (MX1), signal transducer and activator of transcription 1 (STAT-1), bone marrow stromal cell antigen 2 (BST2) and tripartite motif containing 22 (TRIM22), in lupus CD4 1 T cells [36] . Specifically, Zhao et al. confirmed that the methylation level of the IFI44L promoter is a highly sensitive and specific diagnostic marker for SLE [37] . Renaure et al. performed a genome-scale DNA methylation profile and revealed that differentially methylated regions in naive CD4
1 T cells contribute to the development of cutaneous manifestations in SLE [68] . Another large-scale DNA methylation investigation signified that demethylation of several genes, such as CD80, HECT and RLD domain containing E3 ubiquitin protein ligase 5 (HERC5), IFN regulatory factor 7 (IRF7), ISG15 ubiquitin-like modifier (ISG15), ISG20, integrin subunit alpha X (ITGAX) and poly(ADP-ribose) polymerase family member 12 (PARP12), is associated with renal involvement in lupus [69] .
Abnormal DNA methylation in other subtypes of lupus T cells. Despite advances in understanding of the role played by DNA methylation in lupus CD4
1 T cells, DNA methylation alterations might also exist in other subtypes of lupus T cells. Liu et al. concluded that decreased DNMT levels cause demethylation and over-expression of perforin, CD70 and KIR2DL4 in CD4
1 CD28 -T cells [38] . Furthermore, Sunahori et al. found a new methylation-sensitive gene, protein phosphatase 2A (PP2A), which is hypomethylated in CD3
1 T cells from patients with SLE and contributes to the pathogenesis of SLE [39] . Previous studies explored that DNA demethylation is seen in SLE CD4
1 T cells, but not in CD8 1 T cells and peripheral blood mononuclear cells (PBMCs) [67, 70] , while hypermethylation of the glucocorticoid receptor (GR) gene promoter might result in its low expression in PBMCs of patients with SLE [40] . Inevitably, DNA methylation alterations will be found in different subtypes of lupus T cells in the near future.
Aberrant DNA methylation in lupus B cells
With a main focus upon the importance of T cell DNA methylation in SLE, few researchers found that DNA methylation modifications also existed in B cells. Garaud and colleagues discovered that IL-6 might alter CD5 expression levels by inhibiting DNA methylation, causing the activation of B cells in SLE [41] . Although not exclusive, evidence supported the fact that the expression of different B cell-specific factors, including Pax 5 and cytokine production, regulate the development and progressive inactivation of autoreactive B cells by the tight control of DNA methylation [42] . Nakkuntod et al. detected that demethylation of human endogenous retroviruses-K (HREV-K) long terminal repeats 5 (LTR5) is correlated significantly with complement activity in SLE B cells [43] . Furthermore, HRES-1, the prototype of HERV, is demonstrated to be demethylated in SLE B cells [44] .
Aberrant DNA methylation in lupus neutrophils
Aside from the important role of T and B lymphocyte identified in lupus patients, recent evidence has suggested that lupus neutrophils and low-density granulocytes play a vital role in tissue damage in lupus patients [71] . Hirankarn et al. investigated the methylation levels of the interspersed repetitive sequences (IRS) for long interspersed nuclear element 1 s (LINE-1), Alu, HERV-E and HERV-K in the neutrophils from SLE patients, finding that hypomethylation of LINE-1 might affect expression of the genes and consequently contribute to the pathogenesis of SLE [45] . In addition, Brooks et al. considered that hypomethylation of LINE-1 could impact upon the expression of neighbouring genes and contribute to the pathogenesis of SLE [72] . Mavraga et al. found that LINE-1 mRNA transcripts increased in lupus nephritis kidneys and minor salivary gland tissue from Sj€ ogren's syndrome patients are correlated with its DNA demethylation and type I IFN expression [46] . Recently, Coit et al. identified 293 differentially methylated CG sites in neutrophils from SLE patients and revealed consistent demethylation of IFN signature genes in lupus neutrophils, supporting a pathogenic role for neutrophils in lupus [73] .
Apart 
Defect of the signalling pathway and DNA methylation in SLE
In addition to affecting immune cell differentiation and autoantibody formation, DNA methylation may play a vital role in various signalling pathways that are involved in SLE. Previous research found that ras-mitogen-activated protein kinase (MAPK) and extracellular receptor-associated kinase (ERK) pathway are involved in DNA hypomethylation by downregulating DNMT activity in SLE [49, 50] . Oelke et al. showed that DNMT inhibitors, such as 5-azacytidine, might cause drug-induced and idiopathic lupus by inhibiting the ERK signalling pathway [77] . In addition, the inhibition of T cell protein kinase Cd (PKCd), which is an important step in the ERK pathway, leads to the up-regulation of methylationsensitive genes [51] . Protein phosphatase 2Ac (PP2Ac) alters the status of DNA methylation by participating in the phosphorylation of the MEK/ERK pathway [78] . Recently, like the DNMT inhibitors, oxidative stress was reported to cause lupus-like symptoms by inhibiting ERK pathway signalling in T cells leading to DNA demethylation [52, 53] . Interestingly, by genome-scale DNA methylation analysis, Chung et al.
found hypomethylation of CpG sites within genes from different pathways, which is involved in autoantibody production in SLE [79] .
miRNAs, DNA hydroxymethylcytosine and DNA methylation alterations in SLE
Functional studies have demonstrated that a common set of miRNAs play a significant role in the pathogenesis of SLE by modulating immune-related genes and other epigenetic processes. Previous studies identified that under-expression of miR-146a and over-expression of miR-30a are found in patients with SLE, which might be correlated positively with DNA methylation changes [80, 81] . Inhibition of miR-21 and miR-148a expression in lupus CD4 1 T cells could increase DNMT1 expression and attenuate DNA hypomethylation [54] . Correspondingly, increased levels of miR-21 cause the B cell hyperresponsiveness and abnormal T cell response in SLE by targeting the PTEN and PDCD4 genes, respectively [82, 83] . Qin et al. investigated that miR-29b regulated DNMT1 expression negatively, which contributes to DNA hypomethylation of CD4 1 T cells in SLE [55] . Similarly, Zhao et al. detected that miR-126 regulated DNA methylation and causes T cell autoreactivity in SLE by directly targeting DNMT1 [56] . Moreover, Liang et al. explored that miR-126 and its host gene EGF-like domain multiple 7 (EGFL7) expression is up-regulated in CD4 1 T cells from SLE [57] . A previous study confirmed that inhibiting mir-142-3p/5p in healthy donor CD4 1 T cells causes T cell over-activation and B cell hyperstimulation, and a decrease in miR-142 expression in SLE CD4 1 T cells correlates with changes to DNA methylation levels upstream of the miR-142 precursor sequence [58] . As a mechanism that regulates human T cells and stem cells, DNA hydroxymethylcytosine is important for advancing our understanding of the role of DNA demethylation in SLE. Zhao et al. has identified that increased 5-hydroxymethylcytosine in CD4
1 T cells contributes to the abnormal regulation of gene transcription in the pathogenesis of SLE [59] .
DNA methylation alterations in drug-induced lupus
As one of the main symptoms of SLE, drug-induced lupus causes serious damage and has been studied extensively. There are several hypotheses for the underlying mechanism of drug-induced lupus, with DNA methylation inhibition being one of the most widely accepted [6] . Previous studies showed that CD4 1 T cells treated with procainamide or 5-azacytadine causes drug-induced lupus in syngeneic mice [9, 84] . Moreover, almost 100 drugs have been associated with drug-induced lupus, among which procainamide and hydralazine are supposed to inhibit DNA methylation and induce self-reactivity in cloned T cell lines [60] . Intriguingly, hydralazine also represents an epigenetic factor that subverts B lymphocyte tolerance and contributes to the generation of pathogenic autoreactivity by disrupting receptor editing [85] . Also, Mazari et al. suggested that the ERK signalling pathway is impaired in B cells, providing a novel potential B cellmediated mechanism in hydralazine-induced lupus [85] . In addition to certain drugs, environment factors, including ultraviolet light and air pollution, have been implicated in drug-induced lupus by decreasing DNMT1 activity [61] . Current research by Strickland et al. indicates that oxidative stress might cause lupus-like disease by inhibiting ERK pathway signalling in T cells, leading to DNA hypomethylation [52] .
DNA methylation in lupus diagnosis and therapy
As DNA methylation plays significant roles in the pathogenesis in lupus, it might provide novel biomarkers and therapeutic targets for lupus diagnosis and therapy. Zhang et al. showed that a novel approach for measuring the methylation status of CD11a and CD70 could prove to be an effective diagnostic and prognostic test for SLE [86] . Intriguingly, in recent years some drugs have been used in the treatment of SLE by epigenetic modifications. Zhao et al. investigated that total glucosides of peony (TGP) could repress CD11a gene expression by increasing DNA methylation of integrin subunit alpha L (ITGAL) in SLE CD4
1 T cells [62] . Moreover, Yang et al. found that mycophenolate acid (MPA) affects the histone H4 acetylation and histone H3K4 trimethylation levels, thus inhibiting the expression of CD40L in SLE [63] . Recently, Ngalamika et al. considered that measuring FoxP3 T reg -specific demethylated region methylation status could be a useful tool in the diagnosis of autoimmune diseases and chronic microbial infections [64] .
Conclusion and perspectives
Great efforts have been made to explore susceptibility factors in the pathogenesis of lupus. However, there may not be a single simple mechanism by which lupus is induced. Accumulating evidence unravels the involvement of epigenetic modification, particularly DNA methylation, in immune regulation and the pathogenesis of lupus, which enables us to broaden and deepen our understanding of pathogenesis of lupus-like diseases.
In a previous study, we have summarized that methylated alterations vary among different tissue and cell types in autoimmune diseases [87] . Specifically, aberrant DNA methylation varies among different subtypes of T cells in SLE. Although increasing studies have identified that abnormal DNA methylation exists in lupus CD4
1 T cells, its existence in other subtypes of lupus T cells has been reported in only a few studies [39, 40] . Aside from T cells, aberrant methylation of lupus B cells and neutrophils have also played an essential role in lupus patients. Intriguingly, Hirankarn et al. found that hypomethylation of LINE-1 exists in not only CD4
1 T lymphocytes, CD8
1 T lymphocytes and B lymphocytes of SLE patients but also lupus neutrophils [45, 88] , which might be useful in developing a potential biomarker for the diagnosis and therapies for lupus-like diseases. In recent years, aberrant DNA methylation in the PBMCs of lupus patients is also gradually arousing extensive attention. Huang et al. found that hypomethylation of LINE-1 in the PBMCs is associated with risk of juvenile SLE [65] . Moreover, genomewide DNA methylation analysis indicates that there are significant DNA methylation alterations in PBMCs of SLE patients [76, 89] . Although the role of DNA methylation in PBMCs in SLE remains unclear, the development of high-throughput technology is believed to offer additional evidence in the near future to reveal DNA methylation alterations in different types of immune-related cells in the pathogenesis of lupus.
Although multiple genes and different types of cells take part in determining the predisposition to SLE, other susceptibility factors including miRNAs, signalling pathway and environmental factors, largely reflected by DNA methylation alterations, have been demonstrated to be crucial for the pathogenesis of SLE. Notably, some susceptibility factors, such as drugs, are specific to drug-induced lupus. Procainamide and hydralazine, two epigenetic drugs, are found to be involved in drug-induced lupus by inhibiting DNA methylation [9, 10, 60] , which provides useful references for other forms of lupus. In recent years, Freemer et al. found a significantly higher risk of double-stranded DNA seropositivity in smokers [90] . It is possible that such xenobiotics may subvert the Ras-MEK-ERK 1/2 signalling pathway and contribute to lupus-like diseases. Therefore, epigenetic therapy may be worth trying to reverse sitespecific DNA hypomethylation such as inhibiting DNMT1, signalling pathway or transcriptional factors.
In conclusion, understanding the role of aberrant DNA methylation in lupus offers not only novel insights into lupus pathogenesis but also more individually optimized therapeutic strategies for lupus patients in the future.
